(:LMNX)

Jul 12, 2021 06:26 pm ET
Middlesex Water Set to Join S&P SmallCap 600
NEW YORK, July 12, 2021 /PRNewswire/ -- Middlesex Water Co. (NASD: MSEX) will replace Luminex Corp. (NASD: LMNX) in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, July 15. DiaSorin S.p.A. is acquiring Luminex in a deal expected to be completed soon pending final closing conditions.
Jun 08, 2021 02:06 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CNBKA, WRI, FI, SNX, ORBC, LMNX; Shareholders are Encouraged to Contact the Firm
NEW YORK, June 8, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Jun 08, 2021 08:55 am ET
SHAREHOLDER ALERT: WeissLaw LLP Reminds CLDR, LMNX, DTRC, and XEC Shareholders About Its Ongoing Investigations
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th...
Jun 05, 2021 04:50 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates PMBC, LMNX, CNBKA, CADE; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Pacific Mercantile Bancorp (NASDAQ: PMBC) concerning potential violations of the federal securities laws and/or breaches of fiduciary...
Jun 01, 2021 12:14 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Reminds AMRB, LMNX, CADE, and NUAN Shareholders About Its Ongoing Investigations
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th...
May 25, 2021 02:37 pm ET
Lifshitz Law Firm, P.C. Announces Investigation of GBCI, KIM, LMNX and VER
Glacier Bancorp, Inc. (NasdaqGS: GBCI) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the merger of ALTA with GBCI. If you are an investor, and would like information about our...
May 25, 2021 01:00 am ET
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates COG, INSW, PMBC, LMNX; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Cabot Oil & Gas Corporation (NYSE: COG) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties...
May 13, 2021 02:48 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates DSSI, LMNX, EQT, COHR; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Diamond S Shipping Inc. (NYSE: DSSI) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties...
May 07, 2021 06:08 pm ET
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Merger Investigation
Rigrodsky Law, P.A. announces that it is investigating: Welbilt, Inc. (NYSE: WBT) regarding possible breaches of fiduciary duties and other violations of law related to Welbilt’s agreement to be acquired by The Middleby Corporation. To learn...
May 04, 2021 12:34 pm ET
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates LMNX, LEAF, DSSI, WSFS; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Luminex Corporation (NASDAQ: LMNX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties...
Apr 27, 2021 09:21 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Continues to Investigate LEAF, LMNX, NUAN, MFNC; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Leaf Group Ltd. (NYSE: LEAF) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to...
Apr 25, 2021 05:00 am ET
Lifshitz Law Firm, P.C. Announces Investigation of INSW, LMNX, NUAN, and SPRT
International Seaways, Inc. (“International Seaways”) (NYSE: INSW) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the merger of DSSI and INSW. If you are an investor, and would like...
Apr 19, 2021 07:35 pm ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates KNL, STL, AMRB, LMNX; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Knoll, Inc. (NYSE: KNL) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to...
Apr 14, 2021 08:22 pm ET
LUMINEX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Luminex Corporation - LMNX
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Luminex Corporation (NasdaqGS: LMNX) to DiaSorin S.p.A. (OTC: DSRLF). Under the terms of the proposed transaction, shareholders of Luminex will receive only $37.00 in cash for each share of Luminex that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Apr 14, 2021 12:50 pm ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates LMNX, NUAN, CADE, JCS; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Luminex Corporation (NASDAQ: LMNX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties...
Apr 12, 2021 03:21 pm ET
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Luminex Corporation Buyout
Rigrodsky Law, P.A. announces that it is investigating Luminex Corporation (“Luminex”) (NASDAQ GS: LMNX) regarding possible breaches of fiduciary duties and other violations of law related to Luminex’s agreement to be acquired by DiaSorin S.p.A...
Apr 12, 2021 11:41 am ET
LUMINEX CORPORATION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of LMNX and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Luminex Corporation (NASDAQ: LMNX) breached their fiduciary duties or violated the federal securities...
Apr 12, 2021 08:56 am ET
Luminex Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Luminex Corporation Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – LMNX
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Luminex Corporation (NASDAQ: LMNX) to DiaSorin S.p.A. for $37.00 per share is fair to Luminex shareholders.
Feb 19, 2021 05:30 am ET
Luminex Receives BARDA Funding to Support Development and Validation of Test Combining SARS-CoV-2 and Flu/RSV Respiratory Panel
AUSTIN, Texas, Feb. 19, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received $11.3 million in funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services. These funds will support the rapid development and validation of a respiratory panel combining Flu A/B & respiratory syncytial virus (RSV) targets with the SARS-CoV-2 target that can be run on all ARIES® Systems. These 6- and 12-cassette systems are
Feb 08, 2021 03:01 pm ET
Luminex Corporation Reports Fourth Quarter and Full-Year 2020 Results
AUSTIN, Texas, Feb. 8, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced results for its fourth quarter and full-year ended December 31, 2020.
Feb 08, 2021 12:00 pm ET
Luminex Corporation Declares First Quarter Cash Dividend
AUSTIN, Texas, Feb. 8, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company") today announced that its board of directors declared a cash dividend for the first quarter of 2021 of $0.10 per share of common stock payable on April 15, 2021 to stockholders of record as of the close of business March 25, 2021.
Jan 27, 2021 06:00 am ET
Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 8, 2021
AUSTIN, Texas, Jan. 27, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the fourth quarter ended December 31, 2020 on Monday, February 8, 2021. A press release announcing the results is scheduled for release after the close of trading on that date.
Jan 13, 2021 10:14 am ET
Luminex Corporation to Present at 39th Annual J.P. Morgan Healthcare Conference
AUSTIN, Texas, Jan. 13, 2021 /PRNewswire/ -- As previously announced, Luminex Corporation (Nasdaq: LMNX) will present at the 39th Annual J.P. Morgan Healthcare Conference, to be held virtually today, January 13, 2021 at 3:30 p.m. Central Time.  A live webcast of the Luminex presentation has been made available and may be accessed at the company's website at https://investor.luminexcorp.com/events-presentations. The presentation will be available on our website within 24 hours and archived for six months on the website using the 'replay' link.
Jan 12, 2021 05:00 am ET
Luminex Corporation Pre-Release of 4th Quarter 2020 Revenue
AUSTIN, Texas, Jan. 12, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced 4th quarter 2020 revenue of approximately $111M, up approximately 23% over the 4th quarter of 2019 and full-year revenue of approximately $417M, up approximately 25% over the full year 2019. Fourth quarter and full year highlights include:
Dec 16, 2020 01:23 pm ET
Luminex Corporation to Present at 39th Annual J.P. Morgan Healthcare Conference
AUSTIN, Texas, Dec. 16, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced that Nachum "Homi" Shamir, Chairman, CEO and President, and Harriss Currie, Senior Vice President and CFO, will present at the 39th Annual J.P. Morgan Healthcare Conference, to be held virtually, on January 13, 2021 at 3:30 p.m. Central Time.  A live webcast of the Luminex presentation may be accessed at the company's website at http://www.luminexcorp.com. The presentation will be archived for six months on the website using the 'replay' link.
Dec 07, 2020 09:59 am ET
Luminex Corporation Declares Fourth Quarter Cash Dividend
AUSTIN, Texas, Dec. 7, 2020 /PRNewswire/ -- On December 3, 2020, Luminex Corporation (Nasdaq:LMNX) (the "Company"), announced that its board of directors approved a $0.01 increase in the quarterly dividend, to $0.10 per share of common stock, payable on January 14, 2021 to stockholders of record as of the close of business December 23, 2021.
Nov 05, 2020 03:02 pm ET
Luminex Corporation Reports Strong Third Quarter 2020 Results
AUSTIN, Texas, Nov. 5, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced results for its third quarter ended September 30, 2020.
Oct 22, 2020 07:00 am ET
Luminex Corporation Third Quarter Earnings Release Scheduled for November 5, 2020
AUSTIN, Texas, Oct. 22, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the third quarter ended September 30, 2020 on Thursday, November 5, 2020. A press release announcing the results is scheduled for release after the close of trading on that date.
Aug 04, 2020 04:15 pm ET
Luminex Corporation Announces Departure of G. Walter Loewenbaum from Its Board of Directors
AUSTIN, Texas, Aug. 4, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced the retirement of its Chairman, G. Walter Loewenbaum, from its Board of Directors ("Board") effective August 3, 2020. 
Aug 04, 2020 04:01 pm ET
Luminex Corporation Reports Second Quarter 2020 Results
AUSTIN, Texas, Aug. 4, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced results for its second quarter ended June 30, 2020.
Jul 22, 2020 05:00 am ET
Luminex Files for Emergency Use Authorization for Expanded NxTAG Respiratory Panel Test Including SARS-CoV-2
AUSTIN, Texas, July 22, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has submitted an EUA request to the FDA for a new expanded version of its NxTAG® Respiratory Pathogen Panel (RPP) to include the SARS-CoV-2 virus for high-throughput COVID-19 testing. The new test is a combination of the company's original NxTAG RPP, an FDA-cleared in vitro diagnostic for syndromic respiratory infection testing, and the most relevant circulating pathogen today, SARS-CoV-2.
Jul 20, 2020 01:16 pm ET
Luminex Corporation Second Quarter Earnings Release Rescheduled for August 4, 2020
AUSTIN, Texas, July 20, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the second quarter ended June 30, 2020 on Tuesday, August 4, 2020. A press release announcing the results is scheduled for release after the close of trading on that date.
Jul 20, 2020 05:00 am ET
Luminex Receives FDA Emergency Use Authorization for COVID-19 Antibody Test
AUSTIN, Texas, July 20, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the company's xMAP® SARS-CoV-2 Multi-Antigen IgG Assay. Clinical laboratories can now use this serology assay to identify the presence of antibodies in people who have been infected with the virus that causes COVID-19. The test can be run on any of Luminex's xMAP-based high-throughput, gold-standard multiplex platforms, providing a more comprehensive and reliable assessment of immune response compared t
Jul 08, 2020 09:46 am ET
Luminex Corporation Pre-Release of 2nd Quarter 2020 Revenue
AUSTIN, Texas, July 8, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced 2nd quarter 2020 revenues of between $109 and $110 million, up more than 30% over the 2nd quarter of 2019. Highlights include:
Jul 08, 2020 07:00 am ET
Luminex Corporation Pre-Release of 2nd Quarter 2020 Revenue
AUSTIN, Texas, July 8, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced 2nd quarter 2020 revenues of between $109 and $110 million, up more than 30% over the 2nd quarter of 2019. Highlights include:
Jul 01, 2020 05:00 am ET
Luminex Delivers xMAP® INTELLIFLEX Systems to Life Science Research Partners
AUSTIN, Texas, July 1, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the company has delivered the first of its new xMAP® INTELLIFLEX Systems to several of its Life Science Research Partners, achieving a major milestone in the company's strategy to extend its xMAP Technology with new functionality to facilitate new applications. Initially intended for research use only, the new system can double the multiplex capabilities of the xMAP platform, enabling partners and customers to explore new applications. Included in these applications is the unique ability to us
Jun 29, 2020 04:01 pm ET
Luminex Submits Emergency Use Authorization Request to U.S. FDA for COVID-19 Antibody Test
AUSTIN, Texas, June 29, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the company has submitted an Emergency Use Authorization request to the U.S. Food and Drug Administration (FDA) for its xMAP® SARS-CoV-2 Multi-Antigen IgG assay. The assay was developed to provide additional capacity to detect antibodies in patients who may have been exposed to or infected by SARS-CoV-2. It delivers excellent results for up to 96 samples in under three hours and is designed to be run on all xMAP® platforms, with more than 17,000 systems sold globally, and 65+ Luminex global p
May 22, 2020 07:00 am ET
Luminex Corporation Declares Second Quarter Cash Dividend
AUSTIN, Texas, May 22, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) (the "Company"), today announced that its board of directors declared a cash dividend for the second quarter of 2020 of $0.09 per share of common stock payable on July 9, 2020 to stockholders of record as of the close of business June 18, 2020.
May 08, 2020 07:00 am ET
Luminex Corporation Announces Pricing Of Offering Of $260 Million Of 3.00% Convertible Senior Notes Due 2025
AUSTIN, Texas, May 8, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) ("Luminex") announced today the pricing of its offering of $260,000,000 aggregate principal amount of 3.00% Convertible Senior Notes due 2025 (the "Convertible Notes") in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). The delivery of the Convertible Notes to investors in book-entry form is expected to be made on May 13, 2020, and is expected to result in approximately $218.3 million in net proceeds to Luminex after deducting estimated placement agen
May 04, 2020 04:05 pm ET
Luminex Corporation Reports First Quarter 2020 Results
AUSTIN, Texas, May 4, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced results for its first quarter ended March 31, 2020.
Apr 22, 2020 08:30 am ET
Luminex Corporation First Quarter Earnings Release Rescheduled for May 4, 2020
AUSTIN, Texas, April 22, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the first quarter ended March 31, 2020 on Monday, May 4, 2020. A press release announcing the results is scheduled for release after the close of trading on that date.
Apr 06, 2020 04:30 pm ET
Luminex Corporation Pre-Release of 1st Quarter Revenue
AUSTIN, Texas, April 6, 2020 /PRNewswire/ -- Luminex Corporation today announced 1st quarter 2020 revenues of just over $90 million, up approximately 10% over the 1st quarter of 2019 and approximately 8% above the top end of its previously communicated 1st quarter revenue guidance range of $82 to $84 million. Highlights include:
Apr 06, 2020 07:30 am ET
Luminex Receives FDA Emergency Use Authorization for ARIES® SARS-CoV-2 Assay to Detect Virus Responsible for COVID-19 Disease
AUSTIN, Texas, April 6, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its ARIES® SARS-CoV-2 Assay for rapid detection of the virus that causes COVID-19. The assay runs on the ARIES® System, an FDA-cleared, sample-to-answer, automated, on-demand molecular diagnostic platform. The system is capable of running up to 144 tests per day, requiring no specialty training and minimal human interaction. 
Mar 31, 2020 07:30 am ET
Luminex Receives BARDA Contract to Support Development of Second, Rapid SARS-CoV-2 Test
AUSTIN, Texas, March 31, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received $642,450 in funding from the Biomedical Advanced Research and Development Authority (BARDA). These funds will help support development, testing, and submission later this week for an Emergency Use Authorization (EUA) for the ARIES® SARS-CoV-2 Assay. This assay will run on the company's sample-to-answer ARIES® System, an FDA-cleared, automated molecular diagnostics platform for moderate complexity labs.
Mar 27, 2020 04:05 pm ET
Luminex Receives FDA Emergency Use Authorization for NxTAG® CoV Extended Panel to Detect the SARS-CoV-2 Virus that Causes COVID-19 Disease
AUSTIN, Texas, March 27, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its NxTAG® CoV Extended Panel. The intended use of this multiplex test is the detection of the SARS-CoV-2 virus. High complexity molecular laboratories can now use the NxTAG test on Luminex's easy-to-use, compact MAGPIX® System to rapidly detect the virus that causes COVID-19 disease for up to 96 patients in approximately 4 hours. The MAGPIX System, on which the NxTAG panel runs, utilizes Luminex's uni
Nov 04, 2019 02:46 pm ET
Luminex Corporation Reports Third Quarter 2019 Results and Submission of VERIGENE II Gastrointestinal Flex Assay to the FDA
AUSTIN, Texas, Nov. 4, 2019 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced results for its third quarter ended September 30, 2019.
Oct 25, 2019 03:43 pm ET
Luminex Corporation To Release Third Quarter 2019 Results After Market Close On November 4, 2019
AUSTIN, Texas, Oct. 25, 2019 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the third quarter ended September 30, 2019 on Monday, November 4, 2019 after the market close. 
Oct 01, 2019 09:05 am ET
Luminex Receives FDA 510(k) Clearance for the ARIES® MRSA Assay
AUSTIN, Texas, Oct. 1, 2019 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced that the company has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the ARIES® MRSA Assay. The assay is an integrated, real-time, polymerase chain reaction (PCR) based, qualitative, in vitro diagnostic test for the direct detection of methicillin-resistant Staphylococcus aureus (MRSA) DNA from nasal swabs in patients at risk for nasal colonization.
Sep 26, 2019 12:28 pm ET
Luminex Corporation to Present at the Cantor Global Healthcare Conference on October 2, 2019
AUSTIN, Texas, Sept. 26, 2019 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that Homi Shamir, President and Chief Executive Officer, and Harriss Currie, Senior Vice President of Finance and CFO, will participate in investor meetings and present at the Cantor Global Healthcare Conference on Wednesday, October 2, 2019 in New York, NY.
Sep 03, 2019 08:00 am ET
Luminex Corporation to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
AUSTIN, Texas, Sept. 3, 2019 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that Homi Shamir, President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Morgan Stanley 17th Annual Global Healthcare Conference to be held September 9-11, 2019, in New York, NY.
Jul 31, 2019 04:01 pm ET
Luminex Corporation Reports Second Quarter 2019 Financial Results And Increase In Quarterly Dividend
AUSTIN, Texas, July 31, 2019 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced financial results for the second quarter 2019. Financial and operating highlights for the quarter include:
Jul 11, 2019 12:34 pm ET
Luminex Corporation Second Quarter Earnings Release Scheduled for July 31, 2019
AUSTIN, Texas, July 11, 2019 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the second quarter ended June 30, 2019 on Wednesday, July 31, 2019. A press release announcing the results is scheduled for release after the close of trading on that date.
Jul 01, 2019 04:31 pm ET
Luminex Submits ARIES MRSA Assay for FDA Clearance
AUSTIN, Texas, July 1, 2019 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced that the company submitted the ARIES® MRSA Assay to the U.S. Food and Drug Administration (FDA) for clearance on Friday, June 28, 2019. The assay is a real-time, quantitative polymerase chain reaction (qPCR)-based, in vitro diagnostic test for the direct detection of methicillin-resistant Staphylococcus aureus (MRSA) DNA from nasal swabs in patients at risk for nasal colonization.
May 28, 2019 07:07 am ET
EDP Biotech to Develop and Market Colorectal Cancer Early Detection Blood Test Using Luminex xMAP® Technology
KNOXVILLE, Tenn., May 28, 2019 /PRNewswire/ -- EDP Biotech Corporation, an in vitro diagnostics developer focused on early detection of disease, today announced that it has entered into a non-exclusive agreement with Luminex Corporation (NASDAQ: LMNX). According to the terms, EDP Biotech will have the rights to develop, market and sell its blood-based colorectal cancer diagnostic assay, ColoPlex™, using Luminex's xMAP® Technology.
May 21, 2019 02:38 pm ET
Luminex Corporation Declares Second Quarter Cash Dividend
AUSTIN, Texas, May 21, 2019 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company"), today announced that its board of directors declared a cash dividend for the second quarter of 2019 of $0.06 per share of common stock payable on July 11, 2019 to stockholders of record as of the close of business June 20, 2019.
May 14, 2019 08:00 am ET
Luminex Corporation to Present at Upcoming Healthcare Investor Conferences
AUSTIN, Texas, May 14, 2019 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that Homi Shamir, President and Chief Executive Officer, will participate in analyst-led fireside chats at the UBS Global Healthcare Conference to be held May 20, 2019 and at the Jefferies 2019 Global Healthcare conference to be held June 4, 2019.  Both presentations will take place in New York, NY.
May 06, 2019 04:01 pm ET
Luminex Corporation Reports First Quarter 2019 Financial Results
AUSTIN, Texas, May 6, 2019 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the first quarter 2019.  Financial and operating highlights for the quarter include:
Apr 18, 2019 10:37 am ET
Luminex Corporation First Quarter Earnings Release Scheduled for May 6, 2019
AUSTIN, Texas, April 18, 2019 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the first quarter ended March 31, 2019 on Monday, May 6, 2019. A press release announcing the results is scheduled for release after the close of trading on that date.
Mar 05, 2019 09:55 am ET
Luminex Corporation to Present at the Barclays Global Healthcare Conference
AUSTIN, Texas, March 5, 2019 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the Barclays Global Healthcare Conference to be held March 12-14, 2019, in Miami.
Feb 19, 2019 07:30 am ET
Market Trends Toward New Normal in salesforce.com, inc, Genpact, Luminex, Rush Enterprises, Kimball International, and Jones Lang LaSalle — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of salesforce.com, inc. (NYSE:CRM), Genpact Limited (NYSE:G), Luminex...
Feb 08, 2019 01:52 pm ET
Luminex Corporation Declares First Quarter Cash Dividend
AUSTIN, Texas, Feb. 8, 2019 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company"), today announced that its board of directors declared a cash dividend for the first quarter of 2019 of $0.06 per share of common stock payable on April 11, 2019 to stockholders of record as of the close of business March 21, 2019.
Feb 04, 2019 03:21 pm ET
Luminex Corporation Reports Fourth Quarter and Full-Year 2018 Financial Results
AUSTIN, Texas, Feb. 4, 2019 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the fourth quarter and full-year 2018.  Financial and operating highlights for the quarter and full-year include:
Jan 07, 2019 07:00 am ET
Luminex Announces Preliminary Revenue for the Fourth Quarter and Full Year 2018; Company to Present at 37th Annual J.P. Morgan Healthcare Conference
AUSTIN, Texas, Jan. 7, 2019 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced that it expects its revenues in the fourth quarter of 2018 to be approximately $81 million and to exceed $315 million for the full- year ended 2018, near the top of the previously communicated guidance range of $310 to $316 million.
Jan 02, 2019 07:00 am ET
Luminex Corporation Completes Acquisition of MilliporeSigma's Flow Cytometry Portfolio
AUSTIN, Texas, Jan. 2, 2019 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the company has completed its previously announced acquisition of MilliporeSigma's flow cytometry portfolio for $75 million in combined stock, asset and inventory purchases. The acquisition is expected to contribute $40 million to $50 million in revenue to Luminex in 2019.
Dec 11, 2018 12:46 pm ET
Luminex Corporation Declares Fourth Quarter Cash Dividend
AUSTIN, Texas, Dec. 11, 2018 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company"), today announced that its board of directors declared a cash dividend for the fourth quarter of 2018 of $0.06 per share of common stock payable on January 10, 2019 to stockholders of record as of the close of business December 20, 2018.
Dec 11, 2018 07:30 am ET
Report: Exploring Fundamental Drivers Behind Sabre, Catalyst Pharmaceuticals, Renewable Energy Group, Luminex, Parker Drilling, and Apollo Endosurgery — New Horizons, Emerging Trends, and Upcoming Dev
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Sabre Corporation (NASDAQ:SABR), Catalyst Pharmaceuticals, Inc....
Nov 05, 2018 03:01 pm ET
Luminex Corporation Reports Third Quarter 2018 Financial Results
AUSTIN, Texas, Nov. 5, 2018 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced financial results for the third quarter of 2018.  Financial and operating highlights for the quarter include:
Oct 30, 2018 08:00 am ET
XCR Diagnostics and Luminex Enter into License Agreement
Privately held XCR Diagnostics Inc. and Luminex Corporation (Nasdaq:LMNX) have entered into a non-exclusive, worldwide license agreement for XCR's proprietary Xtreme Chain Reaction nucleic acid amplification technology. The XCR technology enables extremely rapid thermal cycling protocols to achieve dramatically reduced ass
Oct 18, 2018 07:55 am ET
Market Trends Toward New Normal in LSC Communications, Corindus Vascular Robotics, Sprouts Farmers Market, Luminex, ChromaDex, and CareDx — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of LSC Communications (NYSE:LKSD), Corindus Vascular Robotics, Inc....
Oct 18, 2018 06:00 am ET
Luminex Corporation to Acquire MilliporeSigma's Flow Cytometry Portfolio
AUSTIN, Texas, Oct. 18, 2018 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the company has signed a definitive agreement to acquire MilliporeSigma's flow cytometry portfolio for $75 million, consisting of approximately $69.9 million to be paid under a Stock and Asset Purchase Agreement and approximately $5.1 million in committed inventory purchases. The deal is expected to close by the end of 2018, and to contribute $40 million to $50 million in revenue to the company in 2019.  
Oct 15, 2018 12:57 pm ET
Luminex Corporation Third Quarter Earnings Release Scheduled for November 5, 2018
AUSTIN, Texas, Oct. 15, 2018 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it expects to report results for the third quarter ended September 30, 2018 on Monday, November 5, 2018. A press release announcing the results is scheduled for release after the close of trading on that date.
Sep 11, 2018 01:36 pm ET
Luminex Corporation Declares Third Quarter Cash Dividend
AUSTIN, Texas, Sept. 11, 2018 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company"), today announced that its board of directors declared a cash dividend for the third quarter of 2018 of $0.06 per share of common stock payable on October 12, 2018 to stockholders of record as of the close of business September 21, 2018.
Sep 06, 2018 04:36 pm ET
Luminex Corporation to Present at the Morgan Stanley 16th Annual Global Healthcare Conference
AUSTIN, Texas, Sept. 6, 2018 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that Homi Shamir, President and Chief Executive Officer, and Harriss Currie, Senior Vice President and Chief Financial Officer, will participate in an analyst-led fireside chat at the Morgan Stanley 16th Annual Global Healthcare Conference to be held September 12-14, 2018 in New York, NY.
Aug 24, 2018 07:50 am ET
Market Trends Toward New Normal in Hornbeck Offshore Services, The Chefs' Warehouse, Installed Building Products, Corindus Vascular Robotics, Capstone Turbine, and Luminex — Emerging Consolidated Expe
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Hornbeck Offshore Services (NYSE:HOS), The Chefs' Warehouse, Inc....
Aug 06, 2018 04:01 pm ET
Luminex Corporation Reports Second Quarter 2018 Financial Results
AUSTIN, Texas, Aug. 6, 2018 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) today announced financial results for the second quarter of 2018.  Financial and operating highlights for the quarter include:
Jul 13, 2018 02:30 pm ET
Luminex Corporation Second Quarter Earnings Release Scheduled for August 6, 2018
AUSTIN, Texas, July 13, 2018 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it expects to report results for the second quarter ended June 30, 2018 on Monday, August 6, 2018. A press release announcing the results is scheduled for release after the close of trading on that date.
Jun 20, 2018 08:25 am ET
Detailed Research: Economic Perspectives on MGM Growth Properties, Acacia Research, Luminex, Eastman Chemical, Mobile Mini, and Kilroy Realty — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MGM Growth Properties LLC (NYSE:MGP), Acacia Research Corporation...
Jun 13, 2018 09:00 am ET
Luminex Initiates Clinical Trials for VERIGENE® II Gastrointestinal Assay
AUSTIN, Texas, June 13, 2018 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced the company recently began clinical studies for the Gastrointestinal (GI) Assay on the VERIGENE® II System, its new sample to answer benchtop molecular diagnostic system in development.
May 18, 2018 04:01 pm ET
Luminex Corporation to Present at Upcoming Healthcare Investor Conferences
AUSTIN, Texas, May 18, 2018 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that Homi Shamir, President and Chief Executive Officer of Luminex will participate in an analyst-led fireside chat at the UBS Global Healthcare Conference to be held May 21, 2018 and will present at the Jefferies 2018 Global Healthcare conference to be held June 5, 2018.  Both presentations will take place in New York, NY.
May 18, 2018 03:42 pm ET
Luminex Corporation Declares Second Quarter Cash Dividend
AUSTIN, Texas, May 18, 2018 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company"), today announced that its board of directors declared a cash dividend for the second quarter of 2018 of $0.06 per share of common stock payable on July 13, 2018 to stockholders of record as of the close of business June 22, 2018.
May 07, 2018 04:01 pm ET
Luminex Corporation Reports First Quarter 2018 Financial Results
AUSTIN, Texas, May 7, 2018 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) today announced financial results for the first quarter of 2018.  Financial and operating highlights for the quarter include:
Apr 27, 2018 08:30 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Bottomline Technologies, SkyWest, Pacific Biosciences of California, Argos Therapeutics, Luminex, and Fiserv — New Research Emphasiz
NEW YORK, April 27, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Bottomline Technologies, Inc. (NASDAQ:EPAY), SkyWest, Inc....
Apr 16, 2018 03:24 pm ET
Luminex Corporation First Quarter Earnings Release Scheduled for May 7, 2018
AUSTIN, Texas, April 16, 2018 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it expects to report results for the first quarter ended March 31, 2018 on Monday, May 7, 2018. A press release announcing the results is scheduled for release after the close of trading on that date.
Mar 08, 2018 01:00 pm ET
Luminex Corporation to Present at the Barclays Global Healthcare Conference
AUSTIN, Texas, March 8, 2018 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the Barclays Global Healthcare Conference to be held March 13-15, 2018, in Miami.
Feb 26, 2018 07:35 am ET
Recent Analysis Shows Luminex, OFG, W.P. Carey, Allstate, Ashford Hospitality Prime, and S&P Global Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Feb. 26, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Luminex Corporation (NASDAQ:LMNX), OFG Bancorp (NYSE:OFG),...
Feb 12, 2018 03:05 pm ET
Luminex Corporation Reports Fourth Quarter and Full-Year 2017 Financial Results
AUSTIN, Texas, Feb. 12, 2018 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the fourth quarter and full-year 2017.  Financial and operating highlights for the quarter and full-year include:
Feb 06, 2018 07:30 am ET
Luminex Corporation To Present At LEERINK Partners 7th Annual Global Healthcare Conference
AUSTIN, Texas, Feb. 6, 2018 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the LEERINK Partners 7th Annual Global Healthcare Conference to be held February 14-15, 2018, in New York, NY.
Jan 24, 2018 03:05 pm ET
Luminex Corporation Declares First Quarter Cash Dividend
AUSTIN, Texas, Jan. 24, 2018 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company"), today announced that its board of directors declared a cash dividend for the first quarter of 2018 of $0.06 per share of common stock payable on April 13, 2018 to stockholders of record as of the close of business on March 23, 2018.
Jan 07, 2018 03:00 pm ET
Luminex Announces Preliminary Revenue for the Fourth Quarter and Full Year 2017; Company to Present at 36th Annual J.P. Morgan Healthcare Conference
AUSTIN, Texas, Jan. 7, 2018 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced that it expects its revenues in the fourth quarter of 2017 to be approximately $78 million and to exceed $306 million for the full- year ended 2017. These expected results reflect increases of 8% and 13% compared to the respective periods in 2016.
Dec 19, 2017 07:40 am ET
Analysis: Positioning to Benefit within Fluor, KB Home, Teradyne, Luminex, OFG, and W.P. Carey — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Dec. 19, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Fluor Corporation (NYSE:FLR), KB Home (NYSE:KBH),...
Dec 13, 2017 03:05 pm ET
Luminex Corporation Declares Fourth Quarter Cash Dividend
AUSTIN, Texas, Dec. 13, 2017 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company"), today announced that its board of directors declared a cash dividend for the fourth quarter of 2017 of $0.06 per share of common stock payable on January 12, 2018 to stockholders of record as of the close of business on December 22, 2017.
Nov 14, 2017 04:05 pm ET
Luminex Corporation To Present At The 29th Annual Piper Jaffray Healthcare Conference
AUSTIN, Texas, Nov. 14, 2017 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced that management will present at the 29th Annual Piper Jaffray Healthcare Conference to be held November 28 -29, 2017, in New York.
Oct 31, 2017 05:05 pm ET
Luminex Corporation Receives FDA Clearance for ARIES Group A Strep Assay
AUSTIN, Texas, Oct. 31, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received FDA clearance for the ARIES® Group A Strep Assay, a moderate complexity, sample to answer test for the direct detection of Streptococcus pyogenes from throat swab specimens using the ARIES® System. This is the sixth assay the FDA has cleared for use on Luminex's ARIES® Systems in the last 24 months.
Oct 30, 2017 05:05 pm ET
Luminex Corporation Reports Third Quarter 2017 Financial Results
AUSTIN, Texas, Oct. 30, 2017 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced financial results for the third quarter of 2017.  Financial and operating highlights for the quarter include the following:
Oct 09, 2017 05:05 pm ET
Luminex Corporation Third Quarter Earnings Release Scheduled for October 30, 2017
AUSTIN, Texas, Oct. 9, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it expects to report results for the third quarter ended September 30, 2017 on Monday, October 30, 2017. A press release announcing the results is scheduled for release after the close of trading on that date.
Sep 19, 2017 05:05 pm ET
Luminex Corporation To Present At Cantor Fitzgerald's Global Healthcare Conference
AUSTIN, Texas, Sept. 19, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at Cantor Fitzgerald's Global Healthcare Conference to be held September 25 -27, 2017, in New York, NY.
Sep 12, 2017 09:30 am ET
Luminex Corporation Declares Third Quarter Cash Dividend
AUSTIN, Texas, Sept. 12, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) (the "Company"), today announced that its board of directors declared a cash dividend for the third quarter of 2017 of $0.06 per share of common stock payable on October 13, 2017 to stockholders of record as of the close of business on September 22, 2017.
Aug 29, 2017 09:30 am ET
Luminex Corporation and Sutter Health Collaborate to Improve Patient Care
AUSTIN, Texas, Aug. 29, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX), and Sutter Health, a not-for-profit health system in Northern California, today announced a collaboration to help advance patient care by improving the health network's ability to quickly and accurately diagnose a range of conditions, including Cystic Fibrosis, gastrointestinal illness, and respiratory tract infections.
Aug 07, 2017 05:05 pm ET
Luminex Corporation Reports Second Quarter 2017 Financial Results
AUSTIN, Texas, Aug. 7, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the second quarter of 2017.  Financial and operating highlights for the quarter include the following:
Jul 24, 2017 09:30 am ET
Luminex Corporation Receives FDA Clearance for ARIES C. difficile Assay
AUSTIN, Texas, July 24, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received FDA clearance for the ARIES® C. difficile Assay, a moderate complexity, sample to answer test for rapid detection of C. difficile. The ARIES® C. difficile Assay detects both toxin A and toxin B, which may reduce the probability of a false negative result from strains that only produce toxin A. This milestone continues the company's track record of a rapid succession of regulatory clearances for assays on the ARIES® Systems, such as Bordetella, GBS and Norovirus CE-IVD earlier
Jul 17, 2017 09:30 am ET
Luminex Corporation Second Quarter Earnings Release Scheduled for August 7, 2017
AUSTIN, Texas, July 17, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it expects to report results for the second quarter ended June 30, 2017 on Monday, August 7, 2017. A press release announcing the results is scheduled for release after the close of trading on that date.
Jun 28, 2017 09:00 am ET
Luminex Corporation Receives CE-IVD Mark for ARIES® Norovirus Assay
AUSTIN, Texas, June 28, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received CE-IVD marking for the ARIES® Norovirus Assay, an easy to use, sample to answer test for rapid detection and differentiation of norovirus genogroup I and II from stool specimens of individuals with symptoms of acute gastroenteritis.
Jun 05, 2017 09:00 am ET
Luminex Corporation's VERIGENE Gram-Positive and Gram-Negative Blood Culture Panels Receive Reimbursement Approval in Japan
AUSTIN, Texas, June 5, 2017 /PRNewswire/ --Luminex Corporation (NASDAQ: LMNX) today announced that Japan's Central Social Insurance Medical Council has approved the recommendation by the Japanese Ministry of Health, Labor and Welfare (MHLW) to provide reimbursement for two VERIGENE® assays: the Gram-Positive Blood Culture (BC-GP) test and the Gram-Negative Blood Culture (BC-GN) test.
May 25, 2017 09:30 am ET
Luminex Corporation To Present At Jefferies 2017 Global Healthcare Conference
AUSTIN, Texas, May 25, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced today that management will present at the Jefferies 2017 Global Healthcare Conference on Thursday, June 8 at 8:30am ET in New York.
May 24, 2017 09:30 am ET
Luminex Corporation Declares Second Quarter Cash Dividend
AUSTIN, Texas, May 24, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) (the "Company"), today announced that its board of directors declared a cash dividend for the second quarter of 2017 of $0.06 per share of common stock payable on July 14, 2017 to stockholders of record as of the close of business on June 23, 2017.
May 03, 2017 09:00 am ET
Luminex Corporation Receives FDA Clearance for ARIES Bordetella Assay
AUSTIN, Texas, May 3, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received FDA clearance for the ARIES® Bordetella Assay for direct detection and identification of Bordetella pertussis (B. pertussis) and Bordetella parapertussis (B. parapertussis) nucleic acid in nasopharyngeal swab specimens obtained from individuals suspected of having a respiratory tract infection attributable to B. pertussis or B. parapertussis. This is the fourth assay the FDA has cleared since October 2015 for use on Luminex's ARIES® Systems. The company has also achieved CE-IVD
May 01, 2017 05:05 pm ET
Luminex Corporation Reports Record First Quarter 2017 Financial Results; Raises 2017 Financial Guidance
AUSTIN, Texas, May 1, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the first quarter of 2017.  Financial and operating highlights for the quarter include the following:
Apr 26, 2017 09:30 am ET
Luminex Corporation To Present At The Deutsche Bank 42nd Annual Health Care Conference
AUSTIN, Texas, April 26, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced today that management will present at the Deutsche Bank 42nd Annual Health Care Conference on Wednesday, May 3, 2017 at 10:00am ET in Boston, Massachusetts.
Apr 20, 2017 09:30 am ET
Luminex Corporation To Present At Bank Of America Merrill Lynch 2017 Health Care Conference
AUSTIN, Texas, April 20, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced today that management will present at the Bank of America Merrill Lynch 2017 Health Care Conference on Tuesday, May 16 at 1:40pm PT in Las Vegas.
Apr 10, 2017 05:05 pm ET
Luminex Corporation First Quarter Earnings Release Scheduled for May 1, 2017
AUSTIN, Texas, April 10, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it expects to report results for the first quarter ended March 31, 2017 on Monday, May 1, 2017. A press release announcing the results is scheduled for release after the close of trading on that date.
Mar 01, 2017 04:05 pm ET
Luminex Corporation To Present At The Barclays Global Healthcare Conference
AUSTIN, Texas, March 1, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the Barclays Global Healthcare Conference to be held at the Loews Miami Beach Hotel March 14 - 16, 2017, in Miami Beach, FL.
Feb 21, 2017 04:05 pm ET
Luminex Corporation Announces Initiation of Cash Dividend
AUSTIN, Texas, Feb. 21, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) (the "Company") today announced that its board of directors has authorized the initiation of a quarterly cash dividend to its shareholders, the first in the company's history.  This initial cash dividend will be payable on April 14, 2017 to shareholders of record as of the close of business on March 24, 2017.
Feb 06, 2017 04:05 pm ET
Luminex Corporation Reports Fourth Quarter And Full Year 2016 Results
AUSTIN, Texas, Feb. 6, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the fourth quarter and full year 2016 ended December 31, 2016.  Financial and operating highlights include the following:
Jan 09, 2017 08:30 am ET
Luminex Announces Preliminary Revenue for Fourth Quarter 2016 and Issues 2017 Revenue Guidance; To Present at 35th Annual J.P. Morgan Healthcare Conference
AUSTIN, Texas, Jan. 9, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it expects revenues in the fourth quarter of 2016 to be approximately $72 million and approximately $271 million for the year. These results reflect increases of 20% and 14% compared to the respective periods in 2015. Verigene-related revenues in the fourth quarter were approximately $9 million, a 32% increase from the year ago period.
Jan 04, 2017 08:00 am ET
Luminex Corporation Receives FDA Clearance for ARIES® GBS Assay
AUSTIN, Texas, Jan. 4, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received FDA clearance for the ARIES® Group B Streptococcus (GBS) Assay for antepartum detection of GBS colonization in pregnant women. This is the third assay the FDA has cleared for use on the Luminex ARIES® Systems. The company has also achieved CE-IVD marking for the ARIES® GBS Assay. 
Dec 05, 2016 08:00 am ET
Luminex wins R&D 100 Award for ARIES Systems
AUSTIN, Texas, Dec. 5, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the company was awarded the prestigious R&D 100 Award for its ARIES® Systems at the 54th Annual R&D 100 Awards ceremony in November. The R&D 100 Awards, presented by R&D Magazine, is an international competition that honors the 100 best technologies of the year. The award recognizes technologically significant products across a wide range of industries, including telecommunications, optics, high-energy physics, materials science, chemistry, and biotechnology, and provides a mar
Nov 17, 2016 08:00 am ET
ARIES System and Flu A/B & RSV Assay Evaluated by Erasmus MC in New Publication
AUSTIN, Texas, Nov. 17, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the internationally renowned Department of Viroscience at Erasmus Medical Center in Rotterdam, The Netherlands, has evaluated the ARIES® System and Flu A/B & RSV CE-IVD Assay for clinical testing in a recently published study. Erasmus MC is a consultation center for the World Health Organization on viral infections, as well as serving as the National Reference Center for Influenza and Emerging Infections in The Netherlands.
Nov 07, 2016 04:05 pm ET
Luminex Corporation To Present At The 28th Annual Piper Jaffray Healthcare Conference
AUSTIN, Texas, Nov. 7, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the 28th Annual Piper Jaffray Healthcare Conference to be held at the Lotte New York Palace November 29 - 30, 2016, in New York, NY.
Oct 31, 2016 05:05 pm ET
Luminex Corporation Reports Third Quarter 2016 Results; Raises Full Year Guidance
AUSTIN, Texas, Oct. 31, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the third quarter ended September 30, 2016.  Financial and operating highlights include the following:
Oct 11, 2016 05:05 pm ET
Luminex Corporation Third Quarter Earnings Release Scheduled for October 31, 2016
AUSTIN, Texas, Oct. 11, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it expects to report results for the third quarter ended September 30, 2016 on Monday, October 31, 2016. A press release announcing the results is scheduled for release after the close of trading on that date.
Aug 08, 2016 09:30 am ET
Luminex Corporation Receives FDA Emergency Use Authorization for Zika Virus Molecular Detection Assay
AUSTIN, Texas, Aug. 8, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a multiplex nucleic acid test designed to detect Zika virus RNA in potentially infected patients using their blood serum, plasma, or urine (collected alongside a patient-matched serum or plasma specimen).
Aug 03, 2016 09:30 am ET
Luminex Corporation Receives FDA Clearance for New Molecular Test for Identification and Differentiation of Influenza A/B and Respiratory Syncytial Virus
AUSTIN, Texas, Aug. 3, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received FDA clearance for the ARIES® Flu A/B & RSV Assay. This is the second assay the FDA has cleared for use on the Luminex ARIES® System.
Jul 28, 2016 05:05 pm ET
Luminex Corporation Reports Second Quarter 2016 Results
AUSTIN, Texas, July 28, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the second quarter ended June 30, 2016.  Financial and operating highlights for the quarter include the following:
Jul 20, 2016 09:30 am ET
Luminex Corporation Second Quarter Earnings Release Scheduled for July 28; Revision to Conference Call Date/Time
AUSTIN, Texas, July 20, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it will now hold a conference call to discuss the second quarter operating highlights and financial results on Friday, July 29, 2016 at 8:30 a.m. Eastern time. This adjustment in call timing was made for the convenience of the investment community. Luminex continues to expect to report results for the second quarter ended June 30, 2016 on Thursday, July 28, 2016 after the close of trading.
Jul 08, 2016 09:30 am ET
Luminex Corporation Second Quarter Earnings Release Scheduled for July 28, 2016
AUSTIN, Texas, July 8, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it expects to report results for the second quarter ended June 30, 2016 on Thursday, July 28, 2016. This reporting date is earlier than usual as a result of the timing of the American Association for Clinical Chemistry's annual conference to be held in Philadelphia from July 31 through August 4. A press release announcing the results is scheduled for release after the close of trading on that date.
Jul 06, 2016 08:00 am ET
Luminex Corporation Receives FDA Clearance and CE-IVD Mark for the ARIES M1 System
AUSTIN, Texas, July 6, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced it has received FDA clearance and CE-IVD marking for a new in vitro diagnostic system, the ARIES® M1 System. Designed for lower throughput clinical labs, the ARIES® M1 System is a fully integrated, sample to answer platform for performing real-time PCR assays.
Jun 30, 2016 09:55 am ET
Luminex Corporation Completes Acquisition of Nanosphere, Inc.
AUSTIN, Texas, June 30, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that Luminex has completed its previously announced acquisition of Nanosphere, Inc. (NASDAQ: NSPH).
Jun 22, 2016 05:05 pm ET
Luminex Corporation To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference
AUSTIN, Texas, June 22, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at Cantor Fitzgerald's 2nd Annual Healthcare Conference to be held July 12 -13, 2016, in New York, NY.
Jun 02, 2016 07:00 am ET
Luminex Corporation Announces Commencement of Tender Offer for All Outstanding Shares of Nanosphere, Inc. Common Stock
AUSTIN, Texas, June 2, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced today that its wholly-owned subsidiary Commodore Acquisition, Inc. has commenced its previously announced tender offer to purchase all outstanding shares of common stock of Nanosphere, Inc. (NASDAQ: NSPH) for $1.70 per share in cash. The tender offer is being made pursuant to the Agreement and Plan of Merger entered into and among Luminex, Commodore, and Nanosphere dated May 15, 2016 as subsequently amended.
Jun 01, 2016 10:15 am ET
Luminex Corporation Receives CE-IVD Mark for ARIES Flu A/B & RSV Assay
AUSTIN, Texas, June 1, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received CE-IVD  status under the European Directive on In Vitro Diagnostic Medical Devices for the ARIES® Flu A/B & RSV Assay. Designed for use with the FDA cleared and CE-IVD marked ARIES® System, the ARIES® Flu A/B & RSV Assay is a rapid and accurate method for the detection and differentiation of three key respiratory pathogens: influenza A virus, influenza B virus, and respiratory syncytial virus (RSV) using a sample to answer platform.
May 26, 2016 05:05 pm ET
Luminex Corporation To Present At Jefferies 2016 Healthcare Conference
AUSTIN, Texas, May 26, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the Jefferies 2016 Healthcare Conference to be held June 7-10, 2016, in New York, NY.
May 23, 2016 07:00 am ET
Luminex Corporation and Nanosphere, Inc. Provide Update on Acquisition Agreement
AUSTIN, Texas and NORTHBROOK, Ill., May 23, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) and Nanosphere, Inc. (NASDAQ: NSPH) announced today that they have entered into an amendment to the definitive agreement under which Luminex will acquire Nanosphere, a leader in the molecular microbiology and molecular diagnostic market.  The purchase price has been increased to $1.70 per share from $1.35 per share in an all cash transaction valued at approximately $77 million. This increase was in response to an unsolicited third party offer for Nanosphere at $1.50 per share. 
May 16, 2016 05:05 pm ET
Luminex to Highlight Latest Additions to Product Portfolio at the 2016 Clinical Virology Symposium
AUSTIN, Texas, May 16, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced it will highlight the latest additions to its product portfolio at the 32nd Annual Clinical Virology Symposium, a meeting of the American Society for Microbiology, taking place May 19-21 in Daytona Beach, Florida. The new ARIES® System will be featured in seven poster presentations, and showcased in a company-sponsored workshop. The recently FDA-cleared and CE-marked NxTAG® Respiratory Pathogen Panel (RPP) will be featured in eight posters. More information, including a select list of Luminex-relat
May 16, 2016 07:00 am ET
Luminex Corporation Signs Definitive Agreement to Acquire Nanosphere, Inc.
AUSTIN, Texas and NORTHBROOK, Ill., May 16, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) and Nanosphere, Inc. (NASDAQ: NSPH) today announced that the companies have entered into a definitive agreement under which Luminex will acquire Nanosphere, a leader in the molecular microbiology and molecular diagnostic market for $1.35 per share in an all cash transaction valued at approximately $58 million.  With its focus on the molecular microbiology segment, Nanosphere delivers proprietary diagnostic tools that enable rapid and accurate detection of respiratory, gastroenteric and bloodst
May 02, 2016 05:05 pm ET
Luminex Corporation Reports First Quarter 2016 Results
AUSTIN, Texas, May 2, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the first quarter ended March 31, 2016.  Financial and operating highlights for the first quarter 2016 include the following:
Apr 28, 2016 09:30 am ET
Luminex Corporation To Present At Investment Conferences In May
AUSTIN, Texas, April 28, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced today that management will present at two upcoming investment conferences in May:
Apr 14, 2016 09:30 am ET
Luminex Corporation Receives FDA Clearance and CE Mark for SYNCT Software
AUSTIN, Texas, April 14, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that its SYNCT™ Software has received both U.S. Food and Drug Administration (FDA) clearance and CE Marking for use with its ARIES® System and NxTAG® assays on the MAGPIX® System. SYNCT Software is middleware that provides access to data and reports through a single interface, and allows for customizable workflows by connecting ARIES® and NxTAG-enabled MAGPIX workstations in the lab.
Apr 11, 2016 05:05 pm ET
Luminex Corporation First Quarter Earnings Release Scheduled for May 2, 2016
AUSTIN, Texas, April 11, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it expects to report results for the first quarter ended March 31, 2016 on Monday, May 2, 2016. A press release announcing the results is scheduled for release after the close of trading on that date.
Apr 07, 2016 08:00 am ET
Luminex Corporation to Showcase CE-IVD Marked ARIES System, Revolutionary Software, and Assays at ECCMID Annual Meeting
AUSTIN, Texas, April 7, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it will showcase its recently CE-IVD marked, sample to answer ARIES® molecular diagnostic system and related assays at the annual meeting of the European Society of Clinical Microbiology and Infectious Diseases (ECCMID) taking place in Amsterdam April 9-12. The new ARIES® System headlines a growing list of featured products from the company for molecular diagnosis of infectious diseases that are designed to improve result accuracy outcomes while reducing overall costs.
Mar 21, 2016 04:00 am ET
Luminex Corporation Receives CE-IVD Mark for ARIES System and ARIES HSV 1&2 Assay
AUSTIN, Texas, March 21, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received CE-IVD marking for the ARIES® System and ARIES® HSV 1&2 Assay. The ARIES® System and ARIES® HSV 1&2 Assay previously received FDA clearance in October 2015 and were subsequently launched in the U.S. market.
Feb 25, 2016 04:09 pm ET
Luminex Corporation Announces Collaboration with University of Sao Paulo to Validate Zika Virus Detection Panel
AUSTIN, Texas, Feb. 25, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced it is collaborating with the Laboratory of Molecular Evolution & Bioinformatics, Biomedical Sciences Institute, University of São Paulo, Brazil to validate a multi-analyte Zika virus assay developed by Luminex partner, GenArraytion, Inc. The MultiFLEX™ Mosquito-borne Panel is now available as a research use only (RUO) multiplex panel designed to detect multiple disease agents, including the Zika virus. Luminex is an exclusive distributor of GenArraytion's MultiFLEX Bioassays.
Feb 22, 2016 04:05 pm ET
Luminex Corporation Receives Medical Device License for ARIES System and ARIES HSV 1&2 Assay in Canada
AUSTIN, Texas, Feb. 22, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received medical device licenses from Health Canada's Therapeutic Products Directorate, Medical Devices Bureau for the ARIES® System and ARIES® HSV 1&2 Assay. The ARIES® System and HSV 1&2 Assay previously received FDA clearance in October 2015 and were subsequently launched in the U.S. market.
Feb 02, 2016 04:05 pm ET
Luminex Corporation To Present At 2016 Leerink Global Healthcare Conference
AUSTIN, Texas, Feb. 2, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the 2016 Leerink Global Healthcare Conference to be held February 10-11, 2016, in New York, NY.
Feb 01, 2016 04:05 pm ET
Luminex Corporation Reports Fourth Quarter And Full Year 2015 Results
AUSTIN, Texas, Feb. 1, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the fourth quarter and year ended December 31, 2015.  Financial and operating highlights for the fourth quarter and full year 2015 include the following:

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.